Immune-mediated platelet depletion augments Alzheimer's disease neuropathological hallmarks in APP-PS1 mice

Aging (Albany NY). 2023 Feb 1;15(3):630-649. doi: 10.18632/aging.204502. Epub 2023 Feb 1.

Abstract

In Alzheimer's disease (AD), platelets become dysfunctional and might contribute to amyloid beta deposition. Here, we depleted platelets in one-year-old APP Swedish PS1 dE9 (APP-PS1) transgenic mice for five days, using intraperitoneal injections of an anti-CD42b antibody, and assessed changes in cerebral amyloidosis, plaque-associated neuritic dystrophy and gliosis. In APP-PS1 female mice, platelet depletion shifted amyloid plaque size distribution towards bigger plaques and increased neuritic dystrophy in the hippocampus. In platelet-depleted females, plaque-associated Iba1+ microglia had lower amounts of fibrillar amyloid beta cargo and GFAP+ astrocytic processes showed a higher overlap with thioflavin S+ amyloid plaques. In contrast to the popular hypothesis that platelets foster plaque pathology, our data suggest that platelets might limit plaque growth and attenuate plaque-related neuritic dystrophy at advanced stages of amyloid plaque pathology in APP-PS1 female mice. Whether the changes in amyloid plaque pathology are due to a direct effect on amyloid beta deposition or are a consequence of altered glial function needs to be further elucidated.

Keywords: Alzheimer’s disease; amyloid-beta; astrocytes; microglia; platelets.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / pathology
  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor / genetics
  • Animals
  • Disease Models, Animal
  • Female
  • Mice
  • Mice, Transgenic
  • Plaque, Amyloid / pathology

Substances

  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor